Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Krystal Biotech, Inc. $KRYS

Key Points

• Connor Clark & Lunn Investment Management Ltd. has acquired a new stake in Krystal Biotech, purchasing 2,582 shares valued at approximately $466,000 during the first quarter.
• Several institutional investors, including Fifth Third Bancorp and GAMMA Investing LLC, have significantly increased their positions in the company, indicating growing interest in Krystal Biotech.
• Wall Street analysts have a generally positive outlook on the stock, with an average rating of "Buy" and an average price target of $210.75, reflecting confidence in the company's growth prospects.

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,582 shares of the company's stock, valued at approximately $466,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Fifth Third Bancorp raised its holdings in Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the period. GAMMA Investing LLC raised its holdings in Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after buying an additional 432 shares during the period. Wells Fargo & Company MN raised its holdings in Krystal Biotech by 21.3% during the 4th quarter. Wells Fargo & Company MN now owns 16,928 shares of the company's stock worth $2,652,000 after buying an additional 2,972 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in Krystal Biotech during the 1st quarter worth about $229,000. Finally, M&T Bank Corp purchased a new position in Krystal Biotech during the 1st quarter valued at about $667,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Citigroup reaffirmed a "neutral" rating and set a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. HC Wainwright reaffirmed a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Friday. Chardan Capital lowered their target price on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research note on Friday. Guggenheim lowered their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, Bank of America lowered their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $210.38.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS traded down $3.72 during trading hours on Monday, hitting $146.77. The stock had a trading volume of 301,636 shares, compared to its average volume of 425,092. The company has a market capitalization of $4.25 billion, a P/E ratio of 29.83 and a beta of 0.70. The firm's 50-day moving average price is $144.50 and its two-hundred day moving average price is $154.44. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. As a group, analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider owned 1,508,056 shares of the company's stock, valued at $226,208,400. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 49,800 shares of company stock worth $7,487,943 over the last three months. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).